Literature DB >> 28875999

A comparison of the human and mouse protein corona profiles of functionalized SiO2 nanocarriers.

A Solorio-Rodríguez1, V Escamilla-Rivera, M Uribe-Ramírez, A Chagolla, R Winkler, C M García-Cuellar, A De Vizcaya-Ruiz.   

Abstract

Nanoparticles are a promising cancer therapy for their use as drug carriers given their versatile functionalization with polyethylene glycol and proteins that can be recognized by overexpressed receptors in tumor cells. However, it has been suggested that in biological fluids, proteins cover nanoparticles, which gives the proteins a biological identity that could be responsible for unexpected biological responses: the so-called protein corona. A relevant biological event that is usually ignored in protein-corona formation is the interspecies differences in protein binding, which can be involved in the discrepancies observed in preclinical studies and the nanoparticle safety and efficiency. Hence, the aim of this study was to determine the differences between human and mouse plasma protein corona profiles in an active therapy model using silicon dioxide nanoparticles (SiO2 nanoparticles) functionalized with polyethylene glycol and transferrin. Functionalized SiO2 nanoparticles were made with a primary particle size of 25 nm and a transferrin content of 50 μg mg-1 of nanoparticles and were PEGylated with a cross-linker. The proteomic analysis by nanoliquid chromatography tandem-mass spectrometry (nanoLC-MS/MS) showed interspecies differences. The most abundant proteins found in the human protein corona profile were immunoglobulins, actin cytoplasmic 1, hemoglobin subunit beta, serotransferrin, ficolin-3, complement C3, and apolipoprotein A-1. Meanwhile, the mouse protein corona adsorbed the serine protease inhibitor A3K, serotransferrin, alpha-1-antitrypsin 1-2, hemoglobin subunit beta, and fibrinogen gamma and beta chains. These protein-corona profile differences in the functionalized SiO2 nanoparticles indicate that biological responses observed in in vivo models could not be translated to clinical use and must be considered in the interpretation of preclinical trials in order to design more efficient and safer nanomedicines.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28875999     DOI: 10.1039/c7nr04685e

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  11 in total

1.  Formation of a protein corona influences the biological identity of nanomaterials.

Authors:  Daniel Nierenberg; Annette R Khaled; Orielyz Flores
Journal:  Rep Pract Oncol Radiother       Date:  2018-05-28

Review 2.  Analysing the nanoparticle-protein corona for potential molecular target identification.

Authors:  Chandra Kumar Elechalawar; Md Nazir Hossen; Lacey McNally; Resham Bhattacharya; Priyabrata Mukherjee
Journal:  J Control Release       Date:  2020-03-09       Impact factor: 9.776

3.  Plasma proteins facilitates placental transfer of polystyrene particles.

Authors:  Michael M Gruber; Birgit Hirschmugl; Natascha Berger; Magdalena Holter; Snježana Radulović; Gerd Leitinger; Laura Liesinger; Andrea Berghold; Eva Roblegg; Ruth Birner-Gruenberger; Vesna Bjelic-Radisic; Christian Wadsack
Journal:  J Nanobiotechnology       Date:  2020-09-09       Impact factor: 10.435

4.  Plasma protein adsorption on Fe3O4-PEG nanoparticles activates the complement system and induces an inflammatory response.

Authors:  V Escamilla-Rivera; A Solorio-Rodríguez; M Uribe-Ramírez; O Lozano; S Lucas; A Chagolla-López; R Winkler; A De Vizcaya-Ruiz
Journal:  Int J Nanomedicine       Date:  2019-03-25

Review 5.  Progress and Hurdles of Therapeutic Nanosystems against Cancer.

Authors:  Marina Martín-Contreras; Saúl A Navarro-Marchal; José Manuel Peula-García; Ana Belén Jódar-Reyes
Journal:  Pharmaceutics       Date:  2022-02-10       Impact factor: 6.321

6.  Considerations for extracellular vesicle and lipoprotein interactions in cell culture assays.

Authors:  Sara Busatto; Yubo Yang; Dalila Iannotta; Irina Davidovich; Yeshayahu Talmon; Joy Wolfram
Journal:  J Extracell Vesicles       Date:  2022-04

Review 7.  Nanoparticles for Inducing Antigen-Specific T Cell Tolerance in Autoimmune Diseases.

Authors:  Naomi Benne; Daniëlle Ter Braake; Arie Jan Stoppelenburg; Femke Broere
Journal:  Front Immunol       Date:  2022-03-22       Impact factor: 7.561

Review 8.  Opsonins and Dysopsonins of Nanoparticles: Facts, Concepts, and Methodological Guidelines.

Authors:  Emanuele Papini; Regina Tavano; Fabrizio Mancin
Journal:  Front Immunol       Date:  2020-10-12       Impact factor: 7.561

9.  The role of human serum and solution chemistry in fibrinogen peptide-nanoparticle interactions.

Authors:  Angela Zapata; Mai-Loan Nguyen; Caleb Ling; Jacqueline Rogers; Sangeetha Domiano; Clive Hayzelden; Korin E Wheeler
Journal:  Nanoscale Adv       Date:  2020-04-21

Review 10.  Hard and Soft Protein Corona of Nanomaterials: Analysis and Relevance.

Authors:  Rafaela García-Álvarez; María Vallet-Regí
Journal:  Nanomaterials (Basel)       Date:  2021-03-31       Impact factor: 5.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.